|
Jul 17
|
Citius Oncology Announces Closing of $9.0 Million Public Offering
|
|
Jul 16
|
Citius Oncology Announces Pricing of $9.0 Million Public Offering
|
|
Jul 15
|
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
|
|
Jun 17
|
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
|
|
Jun 12
|
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
|
|
Jun 10
|
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
|
|
Jun 9
|
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
|
|
Jan 8
|
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
|
|
Dec 31
|
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital
|
|
Dec 30
|
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls
|
|
Dec 30
|
Citius Pharma Reports 2024 Financial Results and Business Update
|
|
Aug 5
|
Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.
|
|
Aug 5
|
TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals
|
|
Jun 11
|
Sidoti Events, LLC's Virtual June Small-Cap Conference
|
|
May 21
|
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
|
|
May 14
|
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
|
|
May 10
|
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
|
|
Apr 30
|
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
|
|
Apr 26
|
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
|
|
Apr 11
|
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
|